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Abstract We have recently described manufacturing of hu-
man induced pluripotent stem cells (iPSC) master cell banks
(MCB) generated by a clinically compliant process using cord
blood as a starting material (Baghbaderani et al. in Stem Cell
Reports, 5(4), 647–659, 2015). In this manuscript, we de-
scribe the detailed characterization of the two iPSC clones
generated using this process, including whole genome se-
quencing (WGS), microarray, and comparative genomic hy-
bridization (aCGH) single nucleotide polymorphism (SNP)
analysis. We compare their profiles with a proposed calibra-
tion material and with a reporter subclone and lines made by a
similar process from different donors. We believe that iPSCs
are likely to be used to make multiple clinical products. We
further believe that the lines used as input material will be used
at different sites and, given their immortal status, will be used
for many years or even decades. Therefore, it will be impor-
tant to develop assays to monitor the state of the cells and their
drift in culture. We suggest that a detailed characterization of
the initial status of the cells, a comparison with some calibra-
tion material and the development of reporter sublcones will
help determine which set of tests will be most useful in mon-
itoring the cells and establishing criteria for discarding a line.
Keywords Induced pluripotent stem cells . Embryonic stem
cells . Manufacturing . cGMP . Consent .Markers
Introduction
Induced pluripotent stem cells (iPSCs) are akin to embryonic
stem cells (ESC) [2] in their developmental potential, but dif-
fer from ESC in the starting cell used and the requirement of a
set of proteins to induce pluripotency [3]. Although function-
ally identical, iPSCs may differ from ESC in subtle ways,
including in their epigenetic profile, exposure to the environ-
ment, their mitochondrial content and perhaps X chromosome
inactivation [4]. These differences are intrinsic to the source of
starting material, and such differences may be further ampli-
fied by the pluripotency induction process [5]. It is important
to note, however, that current studies have shown that these
intrinsic differences between ESC and iPSC do not necessarily
reflect in their functional utility; in fact, several large-scale
analyses have verified that the differences seen are more re-
flective of the allelic diversity of individuals [6, 7]. The degree
of difference seen between iPSC lines from different individ-
uals is in the same range as differences seen between iPSC
lines made from the same donor but different tissues and be-
tween ESC and iPSC [8, 9]. Equally important, the changes
introduced by the process of iPSC generation using non-
integration methods are in the same range as those changes
that are seen when cells are maintained in culture for
prolonged periods [10].
These differences, while of importance to the academic
community, would be largely irrelevant to the regulatory au-
thorities and for the development of an allogeneic or
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autologous product, provided these differences did not alter
the potency or efficacy of the differentiated cells that were
derived from these lines [11]. Indeed, this concept has been
used for hematopoietic stem cell transplants where different
donors (which differ in their allelic background and presum-
ably in the efficacy) have been transplanted without showing
that each sample was functionally identical by in vivo or
in vitro testing [12]. It was presumed that the cells were func-
tioning normally in the donor and that the harvesting process
would not alter the cells (i.e. the cells were minimally manip-
ulated), and one could reasonably infer that no change had
occurred. This concept was extended to sibling or related
transplants and then to matched unrelated donors (MUD)
transplants. Here the inference was that one could reasonably
extend the idea of functional equivalency even though the
transplanted cells were functioning in a different setting.
This concept of functional equivalence was extended to
cord blood, which is used for the same purpose as bone mar-
row but differs in that cord blood is processed differently from
bone marrow and is considered more than minimally manip-
ulated. The regulatory authorities reasoned that if functional
equivalence in in vivo studies showed that cells could be
manufactured reliably and reproducibly, then different groups
using different processes and manufacturing at different sites
could be approved under a Biologics License Application
(BLA). Indeed, five public cord blood banks have been ap-
proved to provide MUD-type transplants for individuals using
a commonly accepted release criteria for functional equiva-
lence. Given the extent of in vivo human data available, no
animal studies were required for the approval process. It is
important to note that the regulatory authorities in the United
States recognized that such licensure requirements should not
be extended to autologous or related cord blood use, such as
that proposed by private cord blood banks; indeed, those
banks are not subject to the same BLA licensure requirements.
This logic has been extended to other autologous therapy
where cells are more than minimally manipulated, such as
autologous T-cells, B cells, dendritic cells, NK cells and mac-
rophages [12]. Each of the cell populations is manufactured in
a lot that is sufficient for one individual, and each lot is intrin-
sically different from another lot and is transplanted in a host
at different stages of illness, where the cells likely encounter
different environments. The authorities have not required that
each lot undergo testing, as would be required for an alloge-
neic product that would be used for hundreds or thousands of
patients. Rather, they have asked people to demonstrate that
the end product obtained after processing is functionally
equivalent [12]. In some cases the authorities have required
that eight or ten samples manufactured be shown to be effec-
tive in an animal model, and in some cases have required
human safety studies of a limited nature [12]. Critical to such
approval has been the necessity of having adequate tests or
comparability data that also assesses function [13].
We have assumed that the regulatory authorities will con-
sider a similar logic for other autologous products or HLA-
matched products, including those derived from iPSC [12].
Therefore, like cord blood, autologous or matched cells will
be regulated differently than allogeneic products derived from
iPSC. We further reasoned that if other groups wished to gen-
erate new lines they could use the same process and the com-
munity could define functional equivalence of these new lines.
Since the lines themselves are merely input material to make
fully differentiated cells, we felt that no animal tests were
required at the iPSC stage; rather, criteria for use for further
downstream processing could be established by in vitro dif-
ferentiation assays and agreed-on quality control (QC) criteria
for pluripotency. Functional characterization and equivalency
of the end product with any necessary in vivo or human stud-
ies would occur on the final manufactured product. As with
other products that may be used for autologous or allogeneic
manufacture, we assume that the tests required will be differ-
ent and the regulations likely different, but in both cases it will
be critical to have comparability data.
Given most groups were initially focusing on allogeneic
therapy, we initiated a program to generate clinically compli-
ant cells and have reported on the generation of two such lines
[1], which we presume will be used to generate a variety of
products from a MCB. Although the process development
was expensive and time consuming [1, 14], we reasoned that
the cost would be amortized over a large number of patients
[15]. Our data suggest that these lines could be used to com-
mercialize iPSC-based cell therapy following a standard
Investigational New Drug (IND) path.
However, it became evident that this was not a viable mod-
el for autologous cells and haplobank-derived cells, as had
become clear with other cell therapies (see above). One would
have to reduce cost and the regulators would need to develop
models akin to those they have developed for cord blood
banks. Therefore, we evaluated what would need to be done
to reduce cost should cells be used for autologous therapy[13]
or if a Haplobank was established[16]. Moreover, since these
lines may be used by a number of individuals and utilized to
generate a number of different products – each of which will
be likely manufactured in a different site by different compa-
nies – we reasoned that additional characterization may be
necessary and that a database to monitor changes in cells in
culture needs to be established. In this manuscript, we de-
scribe the detailed characterization of two cGMP-compatible
iPSC lines using WGS, array-based analysis and aCGH SNP
analysis. One of these lines - LiPSC-GR1.1- generated during
GMP manufacturing runs and the other line - LiPSC-ER2.2 -
generated during engineering runs using the same GMP com-
patible process described before [1]. Our goal is to provide
data to end users to determine which subset of tests will be
required for ongoing monitoring, how such tests should be
used to evaluate use of subclones for preclinical studies or cell
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therapy, and how comparability between manufacturing sites
needs to be established.
Materials and Methods
Generation of Human Induced Pluripotent Stem Cells
Huamn iPSC lines used in the analysis and standard analysis
(Table 1.0) were generated at Lonza Walkersville, Inc. as de-
scribed before [1]. Briefly, cryopreserved human umbilical
Cord Blood (hUCB) CD34+ cells (Lonza, 2C-101) were
thawed and expanded in a priming medium comprised of a
basal medium [including IMDM (Iscove's Modified
Dulbecco's Medium; Life Technologies, 12440–053), Ham’s
F12 (Life Technologies, 31765–035), Chemically Defined
Lipid Concentrate (Life Technologies, 11905–031), Bovine
Serum Albumin Fraction V (Life Technologies, 15260–037),
and Insulin,-Transferrin-Selenium-Ethanolamine (ITS-X)
(Life Technologies, 51500–056)] supplemented with 100 ng/
mL recombinant human (rh)SCF (PeproTech, AF-300-07),
100 ng/ml rhFlt3-ligand (PeproTech, AF-300-19), 20 ng/ml
rhThrombopoietin (PeproTech, 300–18) and 10 ng/ml IL-3
(PeproTech, 200–03). The CD34+ cells were seeded in 12-
well plates (Corning, 3513) at a density of 4–6 × 105 cells
per well. Confluent cells (approximately day 3 post-thaw)
were passaged the day prior to Nucleofection. 1 × 106 hUCB
CD34+ cells were reprogramed using the episomal plasmids
encoding Oct4, Sox2, Klf4, c-Myc and Lin28 and pEB-Tg
[17, 18]. These plasmids were introduced into the cells using
the 4D-Nucleofector™ System and P3 solution Kit (Lonza,
V4XP-3012). After nucleofection, the cells were plated in the
priming medium in a 37 °C humidified incubator containing
5 % CO2 and 3 % O2. In some experimental conditions, thirty
micrograms of Alhydrogel® adjuvant 2 % (InvivoGen, vac-
alu-250) were immediately supplemented into the expansion
medium to enhance the reprogramming efficiency. Two days
post-plating, the cells were transferred into 6-well plates pre-
coated with L7™ hPSC Matrix in the L7 hPSC medium sup-
plemented with 1 μM TGFβ inhibitor (Stemgent, 04–0014).
Cells were placed in a 37 °C humidified incubator containing
5 % CO2 and 3 % O2. The cell culture medium was changed
every other day during the course of reprogramming step until
hiPSC colonies appeared and were isolated for further expan-
sion and characterization.
Embryoid Body (EB) Differentiation
Confluent cultures of human pluripotent stem cell colonies
were dissociated using L7™ hPSC Dissociation Solution.
Cell aggregates were suspended in EB formation medium
consisting of DMEM/F12 (Life Technologies, 11330–032)
containing 10 μM Rock Inhibitor Y27632 (Millipore,
SCM075) and allowed to settle by gravity in a conical tube.
After removing the supernatant, cells were suspended in fresh
EB medium. Cell aggregates were then seeded using a split
ratio of 1:1 on Ultra Low Attachment (Corning, YO-01835-
24) plates and returned to the incubator for 12 to 24 h. Once
large cell aggregates formed, they were collected into a coni-
cal tube and allowed to settle by gravity. The medium was
then removed and replaced with differentiation medium
(80 % DMEM High Glucose (Life Technologies, 11965–
092), 20 % defined fetal bovine serum (Hyclone,
SH30070.03), 1X non-essential amino acids (Life
Technologies, 11140–050), 2 mM L-glutamine (Cellgro/
Mediatech, 25-005-CI) and 55 μM β-Mercaptoethanol (Life
Technologies, 21985–023)). The cell aggregates were placed
on Ultra Low Attachment plates using a split ratio of 1:1 in
0.4 ml differentiation medium/cm2. The culture medium was
then changed every second day for six days. On the seventh
day, EBs were seeded on gelatin-coated plates (EmbryoMax®
ES Cell Qualified Gelatin Solution (Millipore, ES006-B)) at
10 EBs/cm2. The EBs were allowed to attach undisturbed for
2 days. The differentiation medium was changed after the
second day and every other day afterward with 0.4 ml/cm2
differentiation medium. The cultures were prepared for immu-
nocytochemistry on day 14.
Differentiated hPSCs were fixed with 4 % PFA and perme-
abilized with 0.1 % Triton X-100 PBS solution as described
above. After rinsing the fixed cells with PBS-T solution, the
cells were incubated with DPBS containing 10 % goat serum
(Life Technologies, 10000C) for 2 h at room temperature.
Primary antibodies detecting alpha-1 Fetoprotein (Abcam,
ab3980; 1:200 or R&D systems, MAB1369, 1:100), beta III
tubulin (Millipore, MAB1637; 1:400) and Smooth Muscle
Actin (DAKO,M0851; 1:500) were added to blocked cultures
and incubated overnight at 2–8 °C. The cells were rinsed twice
with PBS-T, and the secondary antibody, Alexa Fluor 488-
conjugated goat anti-mouse IgG(H + L) (Life Technologies,
A11001; 1:1000) or Alexa Fluor 494-conjugated goat anti-
mouse IgG(H + L) (Life Technologies, A-11032; 1:1000)
were added and incubated on the cells for at least 2 h at room
temperature. The cultures were then rinsed three times (5 min
each) in 1X DPBS prior to counterstaining with DAPI. The
cells were maintained in 50 % glycerol for analysis.
Flow Cytometry
Flow cytometry of hPSCs was performed when cells reached
approximately 70 to 80 % confluency in hPSC medium. The
cultures were dissociated into a single-cell suspension using a
solution of 0.05 % Trypsin/EDTA (CellGro, 25-052-CI) con-
taining 2 % chick serum (Sigma-Aldrich, C5405). The cells
were fixed and permeabilized for intracellular staining with
the Cytofix/Cytoperm Kit (Becton Dickinson, 554714) fol-
lowing the manufacturer ’s recommended protocol.
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Permeabilized cells were incubated with PE-conjugated anti-
OCT3/4 (R&D Systems, IC1759P) or respective PE-
conjugated anti-IgG isotype control. Extracellular antigens
were detected on unfixed cells stained with PE-conjugated
antigen-specific antibodies and respective isotypes using the
manufacturer’s recommended concentration: anti-TRA-1-60
(Becton Dickinson, 560193), anti-TRA-1-81 (Becton
Dickinson, 560161), anti-IgG3 isotype (Becton Dickinson,
556659); anti-SSEA4 (Becton Dickinson, 560128) and anti-
IgM isotype (Becton Dickinson, 555584). The samples were
then processed through a FACSCanto™ II flow cytometer
(Becton Dickinson). Data were acquired using BD FACS
Diva software and analyzed with Flowjo 7.6 software.
Immunocytochemistry
Human pluripotent stem cells were cultured in the hPSC cell
culture medium. hiPSC colonies present in the cultures on
days 3 through 5 were prepared for immunocytochemical
analysis as follows. The culture medium was aspirated, and
cells were washed twice with 1X Dulbecco’s Phosphate
Buffered Saline (Lonza Biosciences, 17-513 F). The cells
were then fixed in 1X DPBS containing 4 % PFA (Electron
Microscopy Sciences, 15710) for 20 min, then rinsed twice
with PBS-T (0.2 % Tween-20 in 1XDPBS) for 5 min (Sigma-
Aldrich, P9416), followed by a 2 h incubation with 10 %
donkey serum in PBS-T at room temperature. The hPSCs
were then treated with primary antibodies detecting extracel-
lular antigens SSEA4 (Millipore, MAB4304; 1:100), TRA-1-
60 (Millipore, MAB4360; 1:100) and TRA-1-81 (StemGent,
09–0011; 1:100) overnight at 2–8 °C prior to being perme-
abilized for 20 min in 1X DPBS containing 0.1 % Triton
X-100 (Sigma-Aldrich, T9284). A second blocking step with
10% donkey serum solution was performed before incubating
the cells with intracellular primary antibodies overnight at 2–
8 °C. Primary antibodies raised against pluripotency-
associated antigens OCT4 (Abcam, ab19857; 1:350) and
Nanog (R&D Systems, AF1997; 6.7 μg/ml) were used in
combination with the secondary antibodies Cy3-conjugated
Donkey anti-rabbit IgG (Jackson ImmunoResearch, 711-
165-152; 1:200) and Cy3-conjugated donkey anti-Goat IgG
(H + L) (Jackson ImmunoResearch, 805-165-180; 1:200), re-
spectively. Primary antibodies specific for SSEA4 and TRA-
1-60/TRA-1-81 were used in combination with secondary an-
tibodies, Alexa Fluor 488-cojugated donkey anti-mouse IgG
(H + L) (Jackson Immunoresearch, 715-545-150; 1:200) and
Alexa Fluor 488-cojugated donkey anti-mouse IgM (H + L)
(Jackson Immunoresearch, 715-545-140; 1:200), respectively.
All cells were incubated with secondary antibodies for 2 h and
then counterstained with 300 nM DAPI (Life Technologies,
D3571) in 1X DPBS at room temperature for 15–30 min.
Cells were rinsed after permeabilization and between the in-
cubation of the primary and secondary antibodies. 50 %
Glycerol was immediately added to the wells after the final
wash with PBS-T. All fluorescence detection was visualized
using an EVOS® FL all-in-one microscope equipped with
software version 17625.
The immunocytochemistry and staining procedures of hu-
man pluripotent stem cells differentiated into neural lineage
were as described previously [19]. Briefly, cells were fixed
with 4 % paraformaldehyde for 20 min, blocked in blocking
buffer (10 % goat serum, 1 % BSA, 0.1 % Triton X-100) for
one hour, followed by incubation with the primary antibody at
4 °C overnight in 8 % goat serum, 1 % BSA, 0.1 % Triton
X-100. Appropriately coupled secondary antibodies,
Alexa350-, Alexa488-, Alexa546-, Alexa594- or Alexa633
(Molecular Probes, and Jackson ImmunoResearch Lab Inc.,
CA), were used for single or double labeling. All secondary
antibodies were tested for cross reactivity and non-specific
immunoreactivity.
Expression Analysis by Microarray
Total RNAwas isolated using the RNeasy® Mini kit accord-
ing to the manufacturer’s instructions (Qiagen, CA) and hy-
bridized to Illumina Human HT-12 BeadChip (Illumina, Inc.,
CA, performed by Microarray core facility at the Burnham
Institute for Medical Research). All the data processing and
analysis was performed using the algorithms includedwith the
Illumina BeadStudio software. The background method was
used for normalization. The maximum expression value of
gene for probe set was used as the expression value of the
gene. For the processed data, the dendrogram was represented
by global array clustering of genes across all the experimental
samples, using the complete linkage method and measuring
the Euclidian distance. Expression of sample correlations was
a measure of Pearson's coefficient, implemented in R System.
CGH-CHIPAnalysis
CGH-CHIP analysis was carried out using the aCGH+ SNP
service by Cell Line Genetics. Cryopreserved vials of the
iPSCs were submitted to the contract lab to prepare sample
and run the assay per standard procedures summarized below.
The iPSC cryovials were thawed at 37 °C, washed once in
1xPBS, and centrifuged. The supernatant was then removed
and the cell pellet was exposed to proteinase K and RNase and
incubated at room temperature for two minutes. Following the
addition of lysis buffer and incubation at 56 °C for 10 min, the
samples were added to a DNeasy® mini spin column and
attached by centrifugation. Samples were then washed two
times with wash buffer and eluted in suspension buffer.
gDNA samples were then cleaned using a Zymo DNA clean
and concentration column. ChIP DNA binding buffer was
added to the gDNA and added to a Zymo-Spin IC-XL column
by centrifugation. The tube was washed two times with wash
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buffer and then eluted in DNA suspension buffer. DNA con-
centration and quality were determined using a NanoVue™
UV spectrophotometer, Qubit™ Fluorometer, and agarose gel
analysis. The isolated gDNAmust meet the following require-
ments: concentration of ≥1 μg of dsDNA measured by the
Qubit™ Fluorometer; 260/280 Ratio of 1.76-1.9 measured
by NanoVue™ Spectrophotometer; and 260/230 Ratio of
≥1.9 measured by NanoVue™ Spectrophotometer.
Following gDNA isolation, labeling reactions were pre-
pared using the Agilent SureTag Complete Labeling
Protocol for aCGH with 500–1500 ng total (RNase treated)
DNA input. The Agilent microarray aCGH protocol com-
posed of two steps: Labeling of the DNA and hybridization.
First, equal amounts of both test and reference samples (500–
1500 ng) were enzymatically sheared for aCGH + SNP arrays
using a dual DNA digestion with restriction enzymes Rsa1
and Alu1. The test sample DNA was labeled with Cyanine
5-dUTP and the reference DNAwas labeled with Cyanine 3-
dUTP by Exo-Klenow fragment. The labeled DNAwas then
purified, and the labeling efficiency and concentration were
determined using the NanoVue™ UV spec. The test and ap-
propriate reference samples were then combined and dena-
tured. The labeled probes were allowed to hybridize with the
feature on the microarray for 24 h at 65 °C. Finally, the arrays
were stringently washed and scanned at a 3 μM resolution on
an Agilent SureScan Microarray Scanner. Feature data was
extracted, processed and mapped to the human genome
(hg19) using ADM-2 Segmentation Algorithm using Agilent
CytoGenomics.
Whole Genome Sequencing
Whole genome sequencing was performed by Macrogen
Clinical Laboratory (Rockville, MD). The samples were pre-
pared according to an Illumina TruSeq Nano DNA sample
preparation guide. Briefly, the whole genomic DNA was ex-
tracted using the DNeasy® Blood & Tissue Kit according to
manufacturer’s instructions (Qiagen, CA cat#69506). One mi-
crogram of genomic DNA was then processed using the
Illumina TruSeq DNA PCR-Free Library Preparation Kit to
generate a final library of 300–400 bp fragment size.
Completed, indexed library pools were run on the Illumina
HiSeq platform as paired-end 2x150bp runs. FASTQ files were
generated by bcl2fastq2 (version 2.15.0.4) and aligned by
ISAAC Aligner (version 1.14.08.28) to generate BAM files.
SNPs, Indels, structural variants (SV) and copy number vari-
ants (CNV) were detected by ISAAC Variant Caller version
1.0.6 [20]. For the SNPs and Indel, locus reads with genotype
quality less than 30 were removed from analysis. The vcf file
thus generated was annotated using SNPEff Version 4.0e
(http://snpeff.sourceforge.net/) [21] using hg19 reference
genome, dbSNP138 build. The alternate allele frequency for
European descendent samples were obtained from 1000
genome project_phase1_release_v3 and ESP6500 databases.
Samtools was used to obtain basic statistics such as the
number of reads, number of duplicate reads, total reads
mapped and total reads unmapped. SAMSTAT version 1.5.1
(http://samstat.sourceforge.net/) [22] was used to report the
mapping quality statistics. The depth of each chromosome
was computed by Issac variant caller.
The variants derived were used to predict the blood group
phenotypes, with the analytical software Boogie [23]. Blood
group predictions were made for routinely used ABO and Rh
system. Apart from this, predictions for MN- and Rh-
associated glycoprotein systems were also performed for both
the cell lines. Genotype information including the chromo-
some number, genomic position, reference allele, alternate
allele and zygosity of the variants belonging to the genes in-
volved in the above mentioned blood group systems were
provided as an input. Boogie verified the relevant variants in
the input genotype with defined phenotypes in the haplotype
table provided default by the software, based on 1-nearest
neighbor algorithm. The SNV permutation with the most like-
ly phenotype gets the best score. The blood groups thus pre-
dicted were compared with available donor data.
The HLA class I (HLA-A,-B and -C) and II (HLA-DQA1,
−DQB1 and -DRB1) profiles for the iPSC lines were estimat-
ed from the WGS data by software called HLAVBseq, which
was developed by Nariai and colleagues [24]. FASTQ files
were aligned to the reference genome using BWA-MEM to
generate a sam file. This method is based on the alignment of
sequence reads to the genomic HLA sequences that are regis-
tered with IMGT/HLA database. Based on variational
Bayesian inference statistical framework, the expected read
counts on HLA alleles is estimated. The hyper parameter al-
pha zero for paired end data set to 0.01. The average depth of
coverage for each HLA allele was calculated based on the perl
script provided by the authors for 200 bp data. The predicted
HLA types was cross-verified with HLA typing results gener-
ated by HLAssureTM SE SBT kit.
To verify if these cell lines showed any variations in genes
implicated in PD, only the non-synonymous variants were
considered. The variants were prioritized based on the benign
or damaging effect of the amino acid substitutions. The in-
silico predictions program, such as SIFT, bases its predictions
on the degree of conservation of amino acid residues [25],
whereas Polyphen predicts these changes based on the impact
of the amino substitution on the structure and function of the
protein based on physical and comparative considerations
[26], respectively. The scores of SIFT and Polyphen were
computed by dbNSFP[27]. The prioritized variants were
cross-validated with the list of PD related genes obtained from
gene cards (www.genecards.org). The variants shortlisted
were referred to clinvar and MIM_disease databases,
annotated by dbNSFP. The integrative study of WGS and
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expression data was performed to validate if these PD-related
genes showed any variation in their expression against the
control lines H9, H7 and NCRM6 [28].
The Issac variant caller which was used to detect structural
variants for the cell lines showed highest number of deletions,
and hence were considered for the analysis. The variants with
genotype quality <20, reads withMAPQ of zero around either
break-end or unknown exact breakpoint location, and read
pairs that support the variant with low confidence were re-
moved. The filtered variants were annotated for the genes
using UCSC table browser (https://genome.ucsc.edu/cgi-bin/
hgTables). Deletion events were manually viewed by
Integrated Genomics Viewer (IGV) [29] to check for the dip
in the coverage at deletion sites. Bed Tools v2-2.20.1 was used
to check the level of overlap from two sets of genomic coor-
dinates. This data was cross-validated with expression data to
verify if there was any differential expression levels due to
these deletions. These short listed differentially expressed
genes were checked for gene enrichment to verify their impli-
cations in various OMIM_diseases and pathways [30]. A sim-
ilar strategy was followed for duplications [31]. The results
were compared with SNP CHIP data for both the cell lines to
check for the gene overlap, if any. This cross comparison was
made even with the unfiltered SV data, to verify if the genes
identified bymicro array were missed inWGS due to filtering.
To verify the status of the imprinted genes, the published
list of imprinted genes was extracted from the database (http://
www.geneimprint.com/). Allelic depth of the alternate allele,
if <10, was filtered. The number of heterozygous and
homozygous SNPs, INDELS were calculated for these
imprinted genes and verified for the genes overlap with
expression data. The maternal or paternal specific expression
for these genes were reported from the documented data. As
no parental information was available, phasing could not be
conducted on these samples to identify maternal or paternal
specific inheritance pattern of these variants identified by the
WGS.
HLAType Analysis
HLA-typing was carried out by Texas Biogene, Inc.
(Richardson, TX) using HLAssureTM SE SBT typing kits.
The HLAssureTM SE SBT Kit is for determining HLA alleles
using PCR amplification with sequence based typing (PCR-
SBT) methodology. Briefly, the whole genomic DNA was
extracted using the DNeasy® Blood & Tissue Kit according
to the manufacturer instructions (Qiagen, CA cat#69506) and
per requirements suggested by Texas Biogene, Inc. (i.e. DNA
sample with an A260/A280 ratio between 1.65 and 1.8). The
genomic DNA was then analyzed using the HLAssureTM A,
B, C, DRB1, and DQB1 SBT typing kits and AccutypeTM
(HLADB-3.19.0) software per procedure established by
Texas Biogene, Inc.
Karyotype and Short Tandem Repeat (STR)
Karyotype and STR analyses were performed by a qualified
service provider (Cell Line Genetics) using standard methods.
Human G-banding karyotyping was performed in accordance
with FDA Good Laboratory Practice by Cell Line Genetics,
which was audited by Lonza Walkersville, Inc. with clinically
certified cytogeneticists experienced with identifying chromo-
somal abnormalities from pluripotent stem cells. For each cell
line, 20 chromosomes were analyzed from live or fixed cells
in metaphase. The analysis was performed using G-banding
and Leishman stain, and the Cells were analyzed according to
the Clinical Cytogenetics Standards and Guidelines published
by the American College of Medical Genetics [32].
The STR assay utilized PCR and capillary electrophoresis
on a PowerPlex 16 mutiplex STR platform (Promega) to de-
termine a match of ≥80 % of the 16 loci evaluated. Data
analysis was performed with SoftGenetics Genemarker soft-
ware. Each assay was evaluated for off ladder peaks, consid-
ered artifacts, and cross contamination prior to reporting.
MCB Viral Testing
According to FDA regulations, release of allogeneic MCBs
for clinical use requires extensive testing for the presence of
viral contaminates. The scope of the MCB viral testing for
hiPSCs was adjusted based on the cellular characteristics of
pluripotent stem cells and comprised of both in vitro and
in vivo assays [1]. Following preparation of samples per stan-
dard procedures recommended by the contract lab
(BioReliance), samples were submitted to the BioReliance in
appropriate condition and format. BioReliance is fully
accredited for GLP, and all studies conducted by
BioReliance are performed in compliance with the require-
ments of the UK and German GLP Regulations, the US
FDA Good Laboratory Practice Regulations (21 CFR 58),
the Japanese GLP Standard, and the OECD Principles of
Good Laboratory Practice (http://www.bioreliance.com/us/
about-us).
Assay Qualification, Characterizations, and in Process
Control
FlowCytometry Assay for Pluripotent StemCells The flow
cytometry assay for evaluation of human pluripotent stem
cells was qualified according to the current Good
Manufacturing Practices, the International Conference on
Harmonization Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) validation guidelines
[33]. The qualification study was conducted using stage-
specific embryonic antigen-4 (SSEA-4), Tra-1-60, and Tra-
1-81. In addition, Oct4, a transcription factor thought to play
a key role in maintaining the self-renewal and pluripotency of
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the embryonic stem cells [34], was also included in the qual-
ification study. The release criteria for pluripotency markers
were established based on the positive expression of four dif-
ferent markers (SSEA-4, Tra-1-60, Tra-1-81, and Oct3/4) ac-
cording to published data as well as data generated during the
process development phase. Since cord blood derived CD34
positive cells were utilized as a starting material for
reprogramming and generation of the final product hiPSCs,
negative expression of surface marker CD34 was also includ-
ed in the qualification study. Precision (intra-assay, inter-as-
say, and intermediate), accuracy, specificity and sensitivity of
this flow cytometry assay was determined during the qualifi-
cation study. The qualified flow cytometry assay with
established release criteria was later used to evaluate the purity
and identify of human iPSCs.
Quantitative PCR for Evaluation of Residual Plasmid
Clearance Since human induced pluripotent stem cells
(iPSCs) were generated using pEB-C5 (i.e. an EBNA1/OriP
episomal plasmid expressing Oct4, Sox2, Klf4, c-Myc and
Lin28) and pEB-Tg (i.e. an EBNA1/OriP plasmid for transient
expression of SV40 T antigen), a quantitative PCR (qPCR)
assay (BResidual qPCR^) was developed to quantitatively de-
tect residual EBNA/OriP sequences originating from either
pEB-C5 or pEB-Tg. Both pEB-C5 and pEB-Tg are non-
integrating plasmids that are supposed to become clear follow-
ing serially passaging of hiPSCs [18, 35]. Considering the
goal of assay to determine the clinical safety of the hiPSC
clones generated by episomal plasmids, the Residual qPCR
assay was qualified according to the International Conference
on Harmonization Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) validation guidelines.
Accuracy, specificity, limit of detection (LOD), and limit of
quantification (LOQ) were determined during the PCR qual-
ification studies. This qualification study was executed based
on 9 total assays conducted by 3 analysts on 3 separate days
using a validated qPCR machine. Appropriate control posi-
tive, control negative, and reference materials were used in the
qualification study.
Characterization Assays Evaluation of hiPSC colony mor-
phology, plating efficiency of hiPSCs post-thaw, and embry-
oid body (EB) formation were classified as FIO assays due to
the challenges associated with qualification of these assays, in
particular the subjective interpretation of the results. EB for-
mation was used to demonstrate the identity and potency of
hiPSCs by investigating spontaneous differentiation into three
germ layers (i.e. ectoderm, mesoderm, and endoderm) and
evaluating the results through immunofluorescence at the pro-
tein level or qPCR analysis at the transcript level. Post-thaw
plating efficiency was evaluated based on alkaline phospha-
tase (AP) staining. AP, a hydrolase enzyme responsible for
dephosphorylating molecules such as nucleotides, proteins,
and alkaloids under alkaline conditions, has been widely used
for evaluation of undifferentiated pluripotent stem cells, in-
cluding both embryonic stem cells and iPSCs [3, 36–38].
Upon staining, the undifferentiated cells appear red or purple,
whereas the differentiated cells appear colorless. However,
considering the inconsistencies observed in the quality of
AP reagents offered by different suppliers and subsequent
intensity of AP staining, it was difficult to set specifications
and cut-off values for the cells positively stained with AP
marker, which in turn resulted in inability to qualify this assay.
Pluritest
Pluritest is an online bioinformatic assay based on gene ex-
pression collected from Illumina microarray to verify
pluripotency [3, 39]. Pluritest is based on 450 genome-wide
transcriptional profiles. These samples are from multiple lab-
oratories and vary from diverse stem cell samples to differen-
tiated cell types, developing and adult human tissue. 223 sam-
ples are human embryonic stem cells and 41 are from iPSC’s.
Two models were developed to obtain pluripotency and non-
pluripotency, a pluripotency score and a novelty score.
Pluripotency score is based on expression levels from known
pluripotent and non-pluripotent genes in the 450 genome-
wide transcriptional profiles. Unknown samples’ gene expres-
sion levels are compared to the expression levels from the 450
samples, and their pluripotency is based on this comparison.
Novelty score measures the technical and biological variation,
based on comparing samples to well-known PSC s in the
dataset [40].
In Process Assays
One important aspect of the GMP manufacturing process was
to establish appropriate assays at different stages of the pro-
cess to ensure the quality of intermediate materials and mon-
itor the progress of the process during the long manufacturing
process. For instance, a flow cytometry assay was implement-
ed following the isolation of CD34+ cells but before proceed-
ing with the priming step. This step ensured appropriate pop-
ulation of actively proliferating CD34+ cells (i.e. a minimum
of 40 % CD34+ cells) were included in the expansion phase
(priming step) prior to the reprogramming (Nucleofection)
step. Importantly, the selection of best hiPSC colonies for
expansion was based on the quality of hiPSCs observed dur-
ing the expansion phase as well as level of residual plasmid
present in the samples taken from each hiPSC clone. A scor-
ing system was established to evaluate the quality of hiPSC
cultures after isolation and throughout the course of serial
subculturing of the cells based on the attachment of hiPSC
colonies the day after passaging, evaluation of the confluency
and amount of spontaneous differentiation at each passage and
every day, and elapsed time (days) per passage. Following
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selection and establishing the hiPSC clones, in-process sam-
ples were submitted at the end of each passage to detect the
level of residual plasmids (i.e. residual EBNA/OriP se-
quences), using qPCR analysis and by recording the Ct value.
The Ct values and the scores achieved for each clone were
used to evaluate the best clone(s) to use in further manufactur-
ing, scale-up and banking process.
Results
Basic Cell Line Characterization
As we developed a process for cGMP manufacture of hiPSCs
[1, 14], we have generated over fifty lines using different
methods and numerous donors to evaluate an optimal method
that worked reliably and reproducibly in our hands. During the
process development, we identified a critical set of required
tests (Table 1) that were similar to those required for most of
the cell lines. In addition, we added karyotype analysis as a
key release assay, because karyotype abnormalities (e.g. triso-
mies of chromosomes 12 and 17) have been observed with
in vitro cultures of both human ESCs [41, 42] and iPSCs [43],
and these abnormalities are suggested to be characteristics of
malignant germ cell tumors [44, 45]. As no required tests have
been defined by regulatory authorities on determining the
quality of ESC or iPSC lines, we reasoned that determining
performance of the lines based on their use would be a rea-
sonable start. We determined that pluripotency could be deter-
mined by the presence of pluripotency markers that were
assessed by immunocytochemistry using well characterized
and widely accepted markers (Fig. 1), and by performing
Table 1 Assays used to characterize the iPSC lines
Assay Objective Evaluation Criteria Category Tested iPSC Line
Assay Release
Pluripotency Markers Identity & Purity SSEA-4 > 70 %, Tra-1-60 > 70 %, Tra-1-
81 > 70 %,




Karyotype Analysis Safety 46, XX or 46, XY Release
assay
All Lines
Mycoplasma Testing Safety Negative Release
assay
All Lines
Sterility Testing Safety Negative Release
assay
All Lines
Endotoxin Testing Safety Standard QC release (<0.5 EU/ml) Release
assay
All lines
Vector Clearance Safety No trace of episomal plasmid DNA detected Release
assay
All lines





Cell Count & Viability Viability % viability >50; minimum cell number/vial Release
Assay
All Lines




EB Formation Identity & Potency Detection of at least one marker per germ layer FIO* All lines
Gene Array Analysis Identity Clustering with established hPSCs FIO* All Lines
Colony morphology Identity & Purity Characteristic morphology of culture/colonies;
lack of spontaneously differentiated cells
FIO* All lines
Post-thaw Plating Thawing efficiency and
Viability
20+ colonies / vial (after 7 days or 50 %
confluency)
FIO* All Lines
HLATyping Identity HLA-A, B, C, DRB1 and DQB1 FIO* All lines
Type






Identity HiSeq X Human Whole Genome FIO* LiPSC-GR1.1 and
ER2.2Sequence
Table summarizes the tests that were performed on the three engineering run lines and the two cGMP lines (all). Note that the three engineering lines were
generated at different times from the same donor sample (Female), while the two cGMP lines were generated from a different donor (Male)
• For Information Only (FIO)
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functional assays on the ability of the cells to differentiate into
ectoderm, endoderm and mesoderm (i.e. EB formation)
(Fig. 1). In addition, given that iPSC are potentially immortal,
we felt that it would be important to be able to trace the iden-
tity of the cells as they pass through the manufacturing process
and are distributed worldwide. While several methods are
available, we used STR (single tandem based repeat) tracking,
as CLIA certified laboratories perform this test routinely and
results are rapidly available [46]. Examining our process, we
determined that STR typing should be done on the donor
sample prior to the start of the reprogramming step, and it
should be matched to the final iPSC sample taken after the
cryopreservation step at the end of the manufacturing process.
Additional characterization was performed using quantitative
PCR, which included examining residual plasmids clearance.
Furthermore, sterility was carried out as a standard method on
the starting materials (cord blood derived CD34+ cells) and
the final manufactured cell product (see methods).
Mycoplasma and endotoxin tests were also carried out as
standard method on final iPSC products. Figure 2 illustrates
the process flow diagram along with the in-process samples
and associated tests. At the beginning of the process, it was
important to test the sterility of CD34+ cells and purity of
these cells using flow cytometry analysis (in-process QC1);
Fig. 1 Generation, expansion, and characterization of human iPSCs
(LiPSC-ER2.1) - engineering runs. Panel a illustrates priming of
CD34+ Cells isolated from cord blood unit and expanded in culture on
day 3 prior to the nucleofection (Priming), iPSC colony emerged on day 9
post nucleofection (D9 Post-Nucleofection), iPSCs at passage 6 (P6
Colonies), and iPSCs at passage 18 (P18 culture). Panel b illustrates
iPSCs positively stained with OCT4, TRA-1-60, SSEA4, NANOG,
TRA-1-81, and alkaline phosphatase (AP). Panel c shows the iPSCs
expressing the pluripotent stem cell surface markers SSEA4, TRA-1-60,
and TRA-1-81 (dark blue). Light blue exhibits the isotype control. Panel
d shows iPSCs differentiated into embryoid bodies and readily expressed
the markers for early ectoderm (TUJ1), endoderm (Alpha-Feto Protein
(AFP)), and mesoderm (Smooth Muscle Actin (SMA)). DAPI shows the
nuclei stain in blue. The iPSCs demonstrated normal karyotype after 17
passages (e). STR analysis showed that the iPSCs matched the starting
CD34+ donor sample (f). Scale bar in all images in Panel a is 500
microns except the Priming image which is 250 microns. Scale bar in
all images in Panel b is 250 microns except the AP image which is 500
microns. Scale bar in all images in Panel D is 125 microns
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it was also critical to test CD34+ cells for karyotype, take
samples for STR analysis and matching with the final iPSCs,
and evaluate the purity of CD34+ cells at the end of priming
stage (in-process QC2). The karyotype analysis, in particular,
was critical to ensure the starting materials undergoing the
reprogramming process were normal. In-process QC3 was
performed to evaluate the quality of iPSCs selected after the
reprogramming based on the morphology of iPSCs [1] and an
RT-PCR based plasmid clearance test. To confirm plasmid
clearance, in-process QC4 was carried out at multiple pas-
sages before final expansion and banking. These multiple in-
process tests were key to evaluate the quality of iPSCs before
performing a comprehensive characterization of iPSCs
through a wide range of QC tests [47, 48].
An example of such a complete characterization is shown
in Fig. 1 for one of the iPSC lines (LiPSC-ER2.1) produced
during the engineering runs described before [1], and further
detailed information on the tests conducted on the other lines
is provided in Fig. 1 and Tables 1 and 2. Although such a
comprehensive characterization may be deemed sufficient
for these iPSC lines, we felt it was inadequate for the potential
use of iPSC lines and that some additional important data
needed to be collected. This included blood group (ABO
and Rh) and HLA typing at high resolution. We noted that
this was not part of the routine process of donor sample, and
we were unable to return to the donor to obtain blood group
data (Table 2) from one of the tissue acquisition sites.
In summary, this minimal set of tests allowed us to track
each line, define its basic characteristics and provide reason-
able predictability as to the quality of the line and its potential
to differentiate into desired differentiated cell types. The im-
munocytochemistry provided insight not only into the purity
of the sample but also assessed the degree of contaminating
cell populations and provided an unbiased method of compar-
ing cells to established comparability criteria in the future.
However, while these tests may be necessary to evaluate a
minimal level of the cells’ quality, we wondered if these
would be sufficient to eliminate all unwanted cell types, and
unfortunately this was unclear. Minor Karyotypic abnormali-
ties or karyotypic abnormalities in a small percentage of the
cells will be missed. Integration of genes used in the iPSC
generation process will not be recognized, and changes or
mutations in genes that are not functionally important at the
pluripotent stage will be missed. We wondered if one could
increase the predictability of the quality by adding additional
tests, and more importantly, be prepared to add additional tests
that may be required in the future. We have proposed three
additional tests, including CGH array based on hybridization
to complement the karyotyping; a transcriptome analysis; and
a whole genome sequencing (WGS) assay that would
Fig. 2 Human iPSCmanufacturing process flow diagramwith in process
testing of samples. The process for manufacturing of human iPSCs under
defined and cGMP conditions include (1) isolation of CD34+ cells from
fresh cord blood unit, (2) priming CD34+ cells for 4 days, (3)
reprogramming of CD34+ cells into iPSCs using 4D Nucleofector
system and an episomal based technology, (4) isolation of about 9 iPSC
colonies, serial subculturing of iPSCs up to 6 passages, (5) in process
cryopreservation of all iPSC colonies to select the two best iPSC colonies
based on the results of in process control IP-QC3, (6) expansion of two
selected iPSC colonies and confirmation of plasmid clearance, (7) further
expansion into large tissue culture flasks, (8) banking, and (9) final
characterizations and QC testing. Multiple in-process samples (shown
in green) were taken at different stages of the process and submitted for
relevant testing. Each in-process test has been described in the figure. The
number of in-process samples exhibits the number of tests carried out at
each step
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complement the basic analysis and enable one to gather infor-
mation as to critical parameters that need to be assessed for
new lines.
CGH+ SNP Microarray Analysis
We selected a SNP hybridization based assay to provide a
higher-resolutionmap of the state of the cells.We utilized both
clones of the cGMP line and the three engineering lines gen-
erated from the same individual using the same cGMP com-
pliant process to determine the utility of the methodology. We
chose a CLIA-certified provider, and the results are provided
in Table 3 (for GMP lines) and Table 4 (for ENG run lines). As
can be seen in Table 3, although GR1.1 is karyotypically and
phenotypically normal, it has several small duplications and
deletions. (See Table 3 Panel A and B). Comparing the chang-
es seen in GR1.1 and GR1.2, several of the duplications and
deletions were common, suggesting that they preexisted prior
to the initiation of the iPSC process. A smaller but significant
number differed between the two samples and likely were
generated during the process of cell line derivation or propa-
gation in culture. A larger number of alterations were seen in
the engineering clones, and what was surprising was the de-
gree of non-overlap (i.e. uncommon aCGH) (Table 4). Aswith
the ER clones, the detected changes were within the range
described by other groups and included genes known to be
affected in disease as well as genes known to be related to
pathways important in disease [7, 8, 10]. Given the lack of
overlap and because we had access toWGS and transcriptome
analysis from cells at the same passage, we compared the
results with those obtained by WGS (whole genome sequenc-
ing) and microarray expression. As discussed below, these
changes did not appear to correlate with WGS data or alter
transcription levels to any demonstrable extent. Although it is
unclear as to the relevance of these changes, developing a
database of the affected genes will allow us to determine if
further changes occur as cells are propagated and whether
changes in certain genes are common and related to the deri-
vation process used, as has been suggested by some studies [7,
8, 10]. Indeed, in the relatively small sample size we noted that
mutation in GNAS [49] were common in several lines.
Microarray Analysis
We reported a whole genome expression analysis of iPSC
lines generated during process development, training runs,
engineering runs and GMP manufacturing runs [1, 14]. Here
we compared gene expression of 10 iPSC lines generated
from the same manufacturing process. Samples of the cells
were collected for RNA extraction and whole genome expres-
sion analysis conducted using Illumina Bead Array platform
(Human HT-12 v4 Expression BeadChip). We have previous-
ly shown that this platform is suitable for reliable and robust
detection of differential gene expression in a large number of
samples [50, 51]. As a control, we included additional iPSC
and ESC lines as well as a CD34+ sample, from which one
iPSC line was derived and the NSC differentiated from the
iPSC. The list of samples analyzed is reported in
Supplemental Table 1, and the entire gene expression profile
is reported in Supplemental Table 2, available upon request.
Initial data processing was done in GenomeStudio software as
previously described [52]. Whole genome expression raw da-
ta, normalized and non-normalized data can be accessed
through Gene expression accession number of GSE72078.
The quality control tests and the various analyses we per-
formed are summarized in Table 5.
First, we performed the quality control of our data set. The
average number of detected genes for all samples was highly
similar: 11,798.4 ± 701.6 (detection p-value < 0.01; mean
± standard deviation; non-normalized data) and 14,661
± 710.1 (detection p-value < 0.05; mean ± standard deviation;
non-normalized data), and no wide discrepancies in
Table 2 iPSC lines generated by Lonza: STR, HLA, and donor information
Line M/F STR HLAType ABO/RH+/− Ethnicity
LiPSC-GR1.1 M Amelogenin (X, Y); vWA (16); D8S1179 (13, 14); TPOX (8);
FGA (18, 25): D3S1358 (15); THO1 (6, 9.3); D21S11
(31.2, 33.2); D18S51 (14); Penta E (7, 11); D5S818 (11);
D13S317 (9, 11); D7S820 (10, 11); D16S539 (11, 13);





LiPSC-ER2.1 F Amelogenin (X); vWA (16); D8S1179 (14, 15); TPOX (8, 9);
FGA (22, 23): D3S1358 (16, 18); THO1 (8, 9.3); D21S11
(24.2, 30.2); D18S51 (12); Penta E (10); D5S818 (11, 13);
D13S317 (11); D7S820 (8, 10); D16S539 (11, 12); CSF1PO






Table summarizes the information for identity and HLA typing and ethnic background that was collected. This data does not distinguish between clones
from the same individual, and tracing and tracking of clones represents an issue that will require a solution to complement the barcoding and physical
tracking methods we recommend
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hybridization signal intensity distributions were observed (not
shown). The quality of the iPSC was verified by submitting
the samples for the Pluritest assay and the results are shown in
Fig. 3. Pluritest verification of iPSC line PR1.0, TR1.1,
TR1.2, GR1.1, GR1.2, ER2.1, ER2.2, ER2.3 and
XCL1iPSC samples fall within the same pluripotency range
(red lines) of ESC samples and iPSC samples used to develop
Pluritest, as does our added positive controls H14 ESC. The
CD34++ cord blood line and ER2.2 NSC fall into non-
pluripotent range (blue lines), demonstrating that our iPSC
lines correlate with known iPSC and ESC (Fig. 3a).
In order to visualize the overall strength of measured signal
across samples and identify presence of potential outliers, we
plotted the signal-to-noise ratios and high-end intensity varia-
tion (95th percentile of signal intensity, P95) (Fig. 3b) in non-
normalized data. Signal intensity was similar in all tested sam-
ples and no outliers were detected, suggesting matching qual-
ity across microarray samples. Based on technical and biolog-
ical variation, all our iPSC and ESC samples falls within the
novelty score (green), while CD34++ cord blood cells and the
ER2.2 NSC fall outside the novelty score (red) (Fig. 3b). Next,
we calculated the pairwise correlation coefficients (r2) to
Table 3 aCGH-SNP analysis of the iPSCs Manufactured during cGMP runs
Chromosome Start Stop Genes Cytoband LiPSC GR-1.1 LiPSCGR-1.2
List A: Common changes observed in GR-1.1 and GR-1.2
chr2 45,168,836 45,171,902 SIX3 P21 Present Present
chr15 34,695,166 34,841,446 GOLGA8B, GOLGAA8A, MIR1233-1, MIR1233-2 q14 Present Present
chr16 31,959,074 33,773,134 HERC2P4, LOC390705, TP53TG3, TP53TG3B,
LOC653550, SLC6A10P
P11.2 Present Present
chr20 57,463,534 57,464,754 GNAS q13.32 Present Present
chrX 130,813,232 131,201,564 LOC286467, MST4 q26.2 Present Present
chrY 17,130,014 17,630,471 q11.221 Present Present
Total No. of common aCGH 6
List B. Non overlapping changes observed GR-1.1 and GR-1.2
chr2 81,631,218 84,380,876 LOC1720 p12 - p11.2 Present
chr2 166,180,491 166,815,270 SCN2A, CSRNP3, GALNT3, TTC21B q24.3 Present
chr3 46,620,840 46,622,617 TDGF1 p21.31 Present
chr5 124,645,064 128,776,611 GRAMD3, ALDH7A1, PHAX, C5orf48, LMNB1,
MARCH3, FLJ44606, MEGF10, PRRC1, CTXN3,
FLJ33630, SLC12A2, FBN2, SLC27A6, ISOC1
q23.2 - q23.3 Present
chr6 47,311,409 54,276,380 CD2AP, GPR111, GPR115, OPN5, C6orf138, MUT,
CENPQ, GLYATL3, C6orf141, RHAG, CRISP2,
CRISP3, PGK2, CRISP1, DEFB133, DEFB114,
DEFB113, DEFB110, DEFB112, TFAP2D, TFAP2B,
PKHD1, MIR206, MIR133B, IL17A, IL17F, MCM3,
PAQR8, EFHC1, TRAM2, LOC730101, TMEM14A,
GSTA7P, GSTA2, GSTA1, GSTA5, GSTA3, GSTA4,
ICK, FBXO9, GCM1, ELOVL5, GCLC, KLHL31,
LRRC1, C6orf142, TINAG
p12.3 - p12.1 Present
chr7 155,596,206 155,601,974 SHH q36.3 Present
chr10 114,549,196 117,896,129 VTI1A, LOC143188, TCF7L2, HABP2, NRAP, CASP7,
C10orf81, DCLRE1A, NHLRC2, ADRB1, C10orf118,
MIR2110, TDRD1, VWA2, AFAP1L2, ABLIM1,
FAM160B1, TRUB1, ATRNL1, GFRA1
q25.2 - q25.3 Present
chr11 19,664,494 20,906,873 NAV2, LOC100126784, DBX1, HTATIP2, PRMT3,
SLC6A5, NELL1
p15.1 Present
chr12 19,001,106 19,925,941 PLEKHA5, AEBP2 p12.3 Present
chr19 50,816,568 51,294,521 KCNC3, NAPSB, NAPSA, NR1H2, POLD1, SPIB,
MYBPC2, FAM71E1, C19orf63, JOSD2, ASPDH,
LRRC4B, SNAR-F, SYT3, LOC342918, SHANK1,
CLEC11A, GPR32, ACPT
q13.33 Present
chrX 306,955 329,692 PPP2R3B p22.33 Present
Total No. of aCGH 5 6
aCGH-SNP analysis of the iPSCs GR1.1 and GR1.2 which are clones. Panel A identifies common changes detected and Panel B lists non- overlapping
changes. The genes are color coded; Red- Known to be affected in disease. Black –Not reported as affected In database . Teal in a pathway related to
diseaseNote the analysis was done at the same time on the same run. The clones were manufactured in two separate runs
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determine the overall relatedness of samples (data now
shown). The correlation coefficients between the iPSC sam-
ples manufactured using the cGMP compliant process was
greater than 0.9 [1], and no significant difference in gene
expression profiles at a global level was observed among these
iPSC lines and the ESC or iPSC lines previously generated
using similar or different reprogramming methodologies [1,
50]. We then performed unsupervised one-way hierarchical
clustering analysis to group averaged samples according to
the degree of gene expression similarity (Fig. 3c). The results
displayed three distribution features: starting material (CD34+
cells used to generate iPSC), pluripotent stem cells (iPSC and
ESC), and differentiated neuronal cells. Together, these find-
ings indicated good overall quality of the microarray data.
Combination of novelty score and pluripotency score
(Fig. 3d) illustrates iPSC and ESC samples are grouped
Table 4 aCGH-SNP analysis of the iPSCs Manufactured during the
Engineering Runs. aCGH-SNP analysis of the iPSCs ER2.1, ER2.2,
ER2.3 which are clones. Panel A identifies common changes detected
and Panel B lists non- overlapping changes. The genes are color coded;
Red- Known to be affected in disease. Black –Not reported as affected In
database . Teal in a pathway related to disease. Note the analysis was done
at the same time for ER 2.2 and ER 2.3 and on a separate run for ER2.1.
on the same run. The clones were manufactured in three separate runs
Chromosome Start Stop Overlap Genes Cytoband LiPSC ER-2.1 LiPSC ER-2.2 LiPSC ER-2.3
A. Common aCGH between LiPSC ER-2.1, LiPSC ER-2.2, and LiPSC ER-2.3 lines
chr16 34,482,042 34,743,643 100 LOC283914, LOC146481,
LOC100130700
p11.2 - p11.1 Present Present Present
Total No. of Common aCGH 1
B. Uncommon aCGH between LiPSC ER-2.1, LiPSC ER-2.2, and LiPSC ER-2.3 lines
chr2 192,581,125 199,052,600 SDPR, TMEFF2, PCGEM1, SLC39A10, DNAH7,
STK17B, HECW2, CCDC150, LOC100130452,
GTF3C3, C2orf66, PGAP1, ANKRD44, SF3B1,
COQ10B, HSPD1, HSPE1, HSPE1-MOBKL3,
MOBKL3, RFTN2, MARS2, BOLL, PLCL1
q32.3 - q33.1 Present
chr2 193,974,618 199,390,001 SLC39A10, DNAH7, STK17B, HECW2, CCDC150,
LOC100130452, GTF3C3, C2orf66, PGAP1,
ANKRD44, SF3B1, COQ10B, HSPD1, HSPE1,
HSPE1-MOBKL3, MOBKL3, RFTN2, MARS2,
BOLL, PLCL1
q32.3 - q33.1 Present
chr4 45,882 68,211 ZNF595, ZNF718 p16.3 Present
chr4 62,069,285 63,216,102 LPHN3 q13.1 Present
chr5 145,468,046 147,372,489 PLAC8L1, LARS, RBM27, POU4F3, TCERG1,
GPR151, PPP2R2B, STK32A, DPYSL3,
JAKMIP2, SPINK1, SCGB3A2, C5orf46
q32 Present
chr5 146,215,672 147,372,489 PPP2R2B, STK32A, DPYSL3, JAKMIP2, SPINK1,
SCGB3A2, C5orf46
q32 Present
chr5 156,407,838 156,619,217 HAVCR1, HAVCR2, MED7, FAM71B, ITK q33.3 Present
chr6 296,674 418,057 DUSP22, IRF4 p25.3 Present
chr6 296,674 462,491 DUSP22, IRF4 p25.3 Present
chr7 82,012,870 85,939,933 CACNA2D1, PCLO, SEMA3E, SEMA3A, SEMA3D q21.11 Present
chr7 121,256,234 122,561,644 PTPRZ1, AASS, FEZF1, LOC154860, CADPS2,
RNF133, RNF148
q31.32 Present
chr8 7,220,322 7,752,586 ZNF705G, DEFB4B, DEFB103B, DEFB103A,
SPAG11B, DEFB104B, DEFB104A, DEFB106B,
DEFB106A, DEFB105B, DEFB105A, DEFB107A,
DEFB107B, FAM90A7, FAM90A14, FAM90A13,
FAM90A19, FAM90A18, FAM90A8, FAM90A9,
FAM90A10, SPAG11A, DEFB4A
p23.1 Present
chr9 129,453,130 129,725,863 LMX1B, ZBTB43, ZBTB34, RALGPS1 q33.3 Present
chr9 138,157,660 138,283,617 q34.3 Present
chr11 2,016,471 2,024,343 H19, MIR675 p15.5 Present
chr11 26,859,414 28,019,072 FIBIN, BBOX1, CCDC34, LGR4, LIN7C, BDNF-AS1,
BDNF
p14.2 - p14.1 Present
chr11 67,374,414 67,378,114 NDUFV1 q13.2 Present
chr12 19,039,306 20,040,127 PLEKHA5, AEBP2 p12.3 - p12.2 Present
chr13 54,124,303 58,474,271 MIR1297, PRR20B, PRR20C, PRR20D,
PRR20E, PRR20A, PCDH17
q14.3 - q21.1 Present
chr14 107,145,681 107,182,658 q32.33 Present
chr15 22,587,129 22,849,189 GOLGA8DP, GOLGA6L1, TUBGCP5 q11.2 Present
chr20 57,463,534 57,464,754 GNAS q13.32 Present Present
chr22 19,749,830 19,758,306 TBX1 q11.21 Present
chr22 51,063,432 51,110,017 ARSA q13.33 Present
chrX 306,955 319,352 PPP2R3B p22.33 Present
chrX 443,311 445,970 p22.33 Present
chrX 8,514,158 8,547,642 KAL1 p22.31 Present
chrX 53,449,448 53,459,515 SMC1A, RIBC1, HSD17B10 p11.22 Present
Total No. of aCGH 4 15 10
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together, suggesting an empirical distribution of pluripotent
cells (red background). CD34++ cord blood cells and ER2.2
NSC are located closer to the non-pluripotent (blue back-
ground) (Fig. 3d). These results also confirm that Pluritest
can be used as another tool to verify pluripotency of newly
derived iPSC.
In addition to utilizing Pluritest, we reasoned we could also
identify subsets of genes which have been identified as being
PSC cell-specific and compare their levels of expression with
that in other PSC that have been well characterized, such as
XL1 [50, 51]. In addition, markers of CD34+ cells as well as
markers of trophoblast and early differentiating cells can be
examined (see supplementary materials) to assess completed
transformation and the absence of contaminating cells. We
note that the Illumina chips include microRNA and our isola-
tion process preserves small RNA species, allowing us to use
the same array system to assessmicroRNA expression profiles
of the cells. Comparison between the two lines and the other
lines included in this analysis showed that the lines were sim-
ilar in their expression profiles and did not show the presence
of differentiated cell markers (data not shown). In particular,
the expression of positional markers (such as HOX genes) was
absent.
Another factor that may alter the behavior of PSC, which is
unlikely to be assessed by routine tests, is the expression of
imprinted genes. We therefore extracted the list of published
imprinted genes and compared the expression of these genes
in the entire sample set (Supplemental Table 3, available upon
request). Overall the expression patterns were similar, though
we noted a significant difference in the expression of NNAT in
XCL1 iPSC and GR1.2. While the relevance of this observa-
tion is unknown, we believe following the levels of these
genes may be important given their association with disease.
Evaluation of gene expression based on a panel of approx-
imately 325 markers (Supplemental Table 3) – including
markers of pluripotency, gender, imprint, endoderm, meso-
derm and ectoderm) revealed (1) no difference between the
male or female lines, (2) no change in the expression of
imprinted genes, and (3) highly expressed level of several
pluripotency markers including Oct4, Nanog and Sox2 in all
iPSC samples (1). Overall, gene expression profiling of the
lines generated using cGMP compliant process was similar
and similar to previously reported iPSC and ESC lines [52].
To further analyze gene expression data, we compared ex-
pression of genes associated with functional pathways. As an
example we compared the levels of genes involved in Cell
Cycle, as well as genes coded for Transcription factors (TF)
and Growth Factor Receptors (GFR) between iPSC line
ER2.2 and GR1.1. Our results (Supplemental Table 4) showed
no significant differences in gene expression in these path-
ways between the 2 iPSC lines. (Supplemental Table 4).
We also reasoned that one could identify the sex of the
individual using expression of Y chromosome genes, and as-
sess if X chromosome inactivation had occurred in female
samples by examining expression of XIST and the levels of
expression of X chromosome genes and comparing them with
cell lines that have demonstrated X chromosome inactivation
or activation. While this is by no means a definitive test, it
allows one to highlight where further testing is required.
Further information on imprinting can be obtained by identi-
fying the differences between sequences between the two al-
leles of the imprinted genes byWGS and determining whether
expression was from the maternal or paternal allele. Although
we did not perform such an analysis in this work, such anal-
ysis can be readily performed if considered necessary.
An additional analysis that could readily be performed was
assessing if the deletions and duplications reported in the
WGS and SNP/CGH array tests had an effect on gene expres-
sion by preparing a list of deletions and duplications in GR1.1
and GR1.2 and examining the expression of those genes that
are known to be expressed at the PSC stage. No significant
change in expression was detected (Sup Table 3).
We have previously shown that rather than comparing in-
dividual gene expression one can examine the overall























The table summarizes the routine QC tests and the results with GR1.1.
Note that both gene subsets as well as examination of overall quality can
be inferred using tests such as Pluritest, correlation co-efficients and un-
biased hierarchical clustering. The data quality is improved by comparing
to a database and with sufficient numbers of lines one can establish ranges
for a comparability assay
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expression of a particular signaling pathway or a subset of
genes related to a particular disease and examine if there are
any obvious differences in expression [50, 51]. For iPSC, we
reasoned that expression of mitochondrial-related genes and
genes related to cell death may be sensitive predictors of
growth rate and proliferation as data on lines is collected.
Furthermore, mitochondrial mutations account for a large
group of hereditary disorders. We therefore examined the sub-
set of mitochondrial genes to examine if any significant
changes were observed when compared to other iPCS and
ESC lines. These analyses revealed no significant change in
the expression of mitochondrial-related genes (data not
shown).
Overall our results suggest that microarray analysis is a
relatively inexpensive method that allows one to rapidly eval-
uate pluripotency and presence of contaminating cells using a
variety of methods. One can compare expression of specific
subsets of genes that may be critical for the use of these cells
for a specific purpose and importantly provide a referral data-
base to compare the ongoing evolution of the cells as they are
Fig. 3 Pluritest analysis of test and control samples. a. Model-based
multi-class pluripotency score: pluripotency score between red lines
indicates a 95 % pluripotency signature. Samples between blue line
indicates 95 % of non-pluripotent samples. Line PR1.0, TR1.1, TR1.2,
GR1.1, GR1.2, ER2.1, ER2.2, ER2.3, XCL1iPSC and H14 ESC are all
localized between or close to the red lines, hence all pluripotent. The
CD34+ cord blood line and ER2.2 NSC are (negative controls) are
located between the blue lines demonstrates non-pluripotent signature.
b. Novelty Score: This score is based on well-characterized pluripotent
samples, color-coded green and non-pluripotent samples color-coded red.
All iPSC and ES samples are in green demonstrates pluripotent samples,
whereas CD34+ cord blood line and ER2.2 NSC demonstrates non-
pluripotent color-code red. c. Hierarchical Clustering of vst-transformed
samples: Samples were transformed using variance stabilizing
transformation (VST) and robust spline normalization _ENREF_35[40].
Distance on x -axis is based on Pearson correlations. d. Overview: This
combines novelty score on X-axis and Pluripotency score on y-axis. The
red background, where the iPSC and ESC samples are located, suggest
the empirical distribution of pluripotent cells. CD34+ cord blood line and
ER2.2 NSC are located closer to the non-pluripotent background colored
blue
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maintained in culture. Collection of such a database may al-
low us to develop comparability criteria and acceptance and
release assay cut-offs for cell processing.
Whole Genome Analysis
We prepared genomic DNA and used it to perform the WGS
on two iPSC lines, one male and one female, to assess their
overall status. The data was analyzed using the pipeline sum-
marized in Fig. 4a. A list of tests that we have performed using
these data sets is summarized in Table 6. Table 7 summarizes
the QC parameters evaluated. Both the lines passed the stan-
dard QC parameters.
The average number variants identified in both cell lines
were similar and showed uniform patterns in the number of
SNP, INS, DEL, synonymous and non-synonymous variants.
As the number of deletions was higher than insertions or trans-
locations, these were analyzed further (Fig. 4c).
The maximum depth of coverage obtained across each
chromosome for both cell lines are shown in Fig. 4b. Higher
depth of coverage in mtDNAwas observed in both cell lines,
as is to be expected. Y chromosome in LiPSC-ER2.2 dipped
as expected in the female line. The total of 36 variants of Y
chromosome overlapped with the X chromosome from the
LiPSC-GR1.1 (male line). This highlights the issues with as-
signment of sequence data.
Extracting Blood type from the whole genome sequencing
data was predicted by using BOOGIE for four different blood
group systems, namely ABO, MNS, Rh and RhAG (Fig. 5a).
The two cell lines LiPSC-ER2.2 and LiPSC-GR1.1 were dis-
tinguished based on their ABO system, showing blood group
A and O respectively with a high confidence score of 94 and
99. The blood group of LiPSC-GR1.1 matched with that of
the donor data LiPSC-GR1.1 for ABO system (blood group
O), whereas donor information for LiPSC-ER2.2 was unavail-
able for comparison.
Comparing predictions across platforms, we note that SNP
Chip analysis would have predicted the phenotype as O. This
is because the SNP Chip does not pick up the insertions while
WGS does, indicating the power and sensitivity of the WGS.
The same program or similar program can be used to extract
information for the thirty minor blood group antigens that
have been described [53].
As with extracting Blood groups, we reasoned that it
should be possible to use the data to identify the HLA pheno-
types of the cell lines, and we used HLAVBSeq program
(Fig. 5b.). The predicted HLA types had a resolution up to 8
digits. Both iPSC cell lines could be distinguished based on
their class I HLA types along with their average depth of
coverage, whereas class II HLA types show similar genotype
but different depths.
The HLA prediction using the WGS and HLAssureTM SE
SBT platforms was comparable for both the lines with two
differences in DQB1 and DRB1 loci . The genotypes for these
two loci in LiPSC-ER2.2 are DRB1*01/*11 and
DQB1*02:02:01 (365.1): DQB1*03/*05.
Likewise for LiPSC-GR1.1, DQB1*02:02:01 (449.2):
DRB1*04/*08, DRB1*09:21 (18785.9): DQB1*03/*04.
From these results it can be inferred that theWGS gives higher
resolution of the HLA prediction, and this with the coverage
values provide confidence in call. The WGS allows us to
identify the cis or trans type of the HLA types, which is not
feasible by the standard methods of assessment. The DQA1-
DQB1 haplotype in both cell lines was found to be in trans-
isoform.
Our interest was studying Parkinson’s disease (PD), and we
wanted to see if a focused analysis of the data could be per-
formed. So we prepared a list of PD-related genes to assess
their status as an example to how a report can be prepared for
specific, disease-related gene sets.
Both iPSC lines showed 23 unique genes relating to PD,
after filtering for damaging effects of the amino acid substitu-
tion, predicted in-silico by SIFT and Polyphen converted rank
scores computed by dbNSFP. These filtered variants were
verified with the expression data. LiPSC-ER2.2 genes
SYNJ1 and E1F4G1 have been implicated in PD when com-
pared to MIM disease database. Whereas line LiPSC-GR1.1
showed two variants for MAPT gene (rs63750417) and one
variant with SYNJ1 gene (rs2254562), which showed its asso-
ciation with PD (Table 8).
The structural variants identified in WGS were cross-
validated with the results obtained from other platforms such
as microarray and expression data. LiPSC-ER2.2 showed no
overlap of the data obtained fromWGS in comparison to SNP
data in both unfiltered and filtered data (only one clone of
Fig. 4 Whole Genome analysis conducted on two iPSC lines generated
using the cGMP compliant manufacturing process. a. WGS data
characterisation pipeline. This figure outlines the work flow followed in
this study. The filters applied at various stages have beenmentioned in the
methods section. The fastq files were aligned using Isaac aligner to
generate bam file. The bam file generated was checked for its mapping
quality using samstat. The fastq files were also used for prediction of
HLA types using HLAVBseq. The variants called by Issac variant caller
was annotated using SnpEff and this data was used for predicting blood
groups using BOOGIE. Only non-synonymous variants were considered
for its implication with PD and cross validated with expression data.
Structural variation (deletions and duplications) were filtered (see
methods) and annotated for genes using UCSC. This data was cross
validated with expression and microarray data. The differentially
expressed genes were verified for gene enrichment relevant to disease
and pathway through DAVID. b. The x-axis shows the various
chromosomes and Y-axis represents the max-depth computed by Issac
Variant Caller across each chromosome on a log scale for both the cell
lines under study. c. Bar graph representing number of variants identified
for SNPs, small Insertions, small deletions, synonymous, non-
synonymous variants, CNVs and different types of structural variants
including duplications, large insertions (length > 50), large deletions
(length > −50), inversions and translocations. Deletions were higher in
number than other types of SVs
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LiPSC-ER2.2 showed overlap of PPP2R2B gene across both
these platforms). The LiPSC-GR1.1 showed overlap of
CSRNP3 and PPP2R3B in the unfiltered data from WGS.
But the genes were removed due to bad quality in the filtered
set of theWGS. TheCSRNP3 gene had a discrepancy that was
considered as GAIN in microarray data, andWGS data shows
it to be a deletion event. This data is summarized in Table 9
along with the log fold change in relation to the control lines
H9_H7 and NCRM6.
To verify if the genes overlapping with structural variants
identified fromWGS- filtered data set showed any implication
with known diseases or pathways, we tested for gene enrich-
ment through DAVID. The line LiPSC-ER2.2 showed no sig-
nals with disease association or pathways for deletion event.
For duplication event, HTR6, GRIK3, OPRD1 were found to
be associated with chemdependency and was enriched for
pathway Eicosanoid Metabolism but with only 2 genes
(CYP2J2, PTGER3).
The LiPSC-GR1.1 line showed no disease-specific enrich-
ment but was enriched for T Cytotoxic Cell Surface
Molecules, T Helper Cell Surface Molecules pathways for
deletion event and no enrichment was found with the duplica-
tion event (Table 10).
To check the status of the imprinted genes, the list of pub-
lished imprinted genes were obtained from the database
(http://www.geneimprint.com). Genes with the status of
imprinted and predicted were considered for the analysis. In
LiPSC-ER2.2 cell line, a total of 148 of 203 genes were
identified with an adequate depth of coverage. Similarly for
LiPSC-GR1.1 cell line, a total of 147 of 203 genes were
identified.
We also examined the expression of these imprinted genes
at the iPSC stage by microarray analysis. LiPSC-ER2.2 and
LiPSC-GR1.1 exhibited detectable expression of 121 and 120
genes respectively (Table 11). The number of homozygous,
heterozygous SNPs, INDELS for these genes and its docu-
mented inheritance are given in Table 11. Thus, the variants
that show the differences in both the chromosomes for
imprinted genes could be extracted. Given the parental infor-
mation we would be able to phase the data to identify the
paternal or maternal specific allele expression in future by
combining this data with RNA sequencing data.























The table summarizes the routine QC tests and the results with GR1.1.
Note that both gene subsets as well as examination of overall quality can
be inferred using tests such as Pluritest, correlation co-efficients and un-
biased hierarchical clustering. The data quality is improved by comparing
to a database and with sufficient numbers of lines one can establish ranges
for a comparability assay
Table 7 Basic QC analysis of
WGS data. Basic QC and
mapping quality summary
statistics for both the cell lines
computed using samtools and
Samstat
QC anlysis Summary LiPSC-ER2.2 LiPSC-GR1.1
Total reads 840146878 898394686
Total reads mapped 33656253 768473456
Mean depth 34.49 30.83
deduplicated reads 90375272 157504614
Total reads after removing duplicates (%) 749771606 (89.2 %) 740890072 (82.5 %)
Reads mapped to human genome 693727158 613291081
MAPQ> =30 86.9 % 79.6 %
MAPQ <30 0.1 % 0.0 %
MAPQ <20 0.5 % 0.5 %
MAPQ <10 0.7 % 0.7 %
MAPQ <3 0.3 % 0.3 %
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We have provided the examples of certain tests that could
be conducted with the WGS data. We can further utilize the
data generated by this platform to determine the mycoplasma
contamination, presence of foreign DNA and other infectious
agents as these would be present as unmapped reads. WGS
analysis can be further extended to extract and annotate mito-
chondrial sequences, STR verification, detect the genotypes of
other transplant antigens and identify plasmid/viral insertions.
Discussion
We have shown that we can use small amounts of
material to analyze samples with high content tests
that yield useful results. For cGMP manufacturing,
we have divided these tests into those required by
regulatory authorities as part of a release criteria and
tests that we classified as for information only (FIO).
We have, however, argued that while not required,
some subset of these tests should be incorporated into
a routine testing process, as this new cell type was
being considered as stating material for cell therapy
for a variety of products. Our rationale for the type
of tests proposed here was based on practical and
theoretical consideration. Cells are intrinsically variable
and can change during the manufacturing process as
well as after implantation as they respond to the en-
vironment. Designing predictive tests for release is
difficult in these circumstances. In addition, current
models for therapy suggest that primary cells will be
used where each lot will come from different starting
material, or Haplobanks will be considered where
Fig. 5 Extracting blood type and
HLA from the whole genome
sequencing data. a.
Table showing the blood group
predicted by BOOGIE for four
different blood group systems
namely ABO, Rh, MN and Rh
associated glycoprotein with the
score for both the cell lines. The
validity of this approach is
provided as means of comparison
with the actual available donor
information. b. Table showing
HLA types predicted in-silico by
HLAVBseq using WGS data for
both the cell lines along with their
depth. The predicted HLA type
obtained using the WGS data is
compared with the results
obtained using the HLA
AssureTM SE SBT kit
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multiple lines will be used to provide the same end
product. We, therefore, approached this issue of com-
parability or equivalency by asking what factors un-
derlie biological variability, and whether there are
some simple tests that can provide data in an unbi-
ased way that if collected in a database over time
would allow us to infer what critical parameters one
will need to monitor.
We proposed a transcriptome analysis, a SNP-CHIP/CGH
array, and whole genome sequencing as three basic tests to
complement the standard tests for pluripotency, differentiation
ability and composition that are routine. It is widely agreed
that karyotyping provides important information, both as an
initial quality control as well as an ongoing measure of the
quality of the cells, and changes in karyotype are indicative of
a change in the quality of the cells. We have, however, sug-
gested that while useful it may not be sensitive enough to
predict changes in the differentiation behavior of cells or other
more subtle defects that may or may not be relevant. An alter-
native strategy that provides additional information while re-
quiring small amounts of material is a SNP-CHIP/CGH anal-
ysis [54, 55] where genomic DNA is hybridized to a reference
genome chip set and changes across the entire genome are
examined using markers ranging in number from 500 K to a
million. The assay is rapid and has the advantage that addi-
tional SNP’s can be added and the chip customized as new
information becomes available. Our data showed that all lines
that were karyotypically normal also carried a number of de-
letions or duplications that included genes that are known to
be altered in specific diseases or are important in their devel-
opment. Some of these were identical in lines made from the
same individual, indicating that they were present prior to the
iPSC generation process while others were induced during the
process. Although the N is small we did notice that an ampli-
fication of GNAS was present in samples from two individ-
uals, and we suggest that monitoring this region in other lines
will be important to determine if this is an anomaly or of
relevance. Thus, SNP-CHIP analysis can reliably be used to
monitor the karyotypic stability over time, and if a database is
established then the relevant importance or frequency of a
deletion or duplication can be inferred over time, so appropri-
ate regulations on use of a line carrying a higher risk can be
established.
To verify if long term cell culturing, passaging has not
altered the genetic integrity of the cell lines generated and
to verify the contamination issues arising due to certain
laboratory practices, we also suggested to use whole ge-
nome sequencing as the WGS, in addition to confirming
SNP-CHIP analysis, can be used to provide data on the
state of the starting material and serve as a reference to
any changes that occur in this population over time. The
wealth of data is of immediate utility in providing a high-
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individuals that may have predictive value. In addition, as
we have shown in the results, WGS provides significant
additional value. We, for example, used standard software
tools (BOOGIE and HLA VBSeq) to infer minor blood
group antigens and high-resolution HLA typing. This in-
formation is difficult to assess without expensive tests and
is not done routinely; the WGS if performed on iPSC cells
could provide an initial signal as to the importance of
testing recipients for particular phenotypes or minor blood
group antigens.
Cross-species contamination (such as bacterial, viral
or mouse) and its relative abundance in the cell lines
can be estimated from the unmapped regions of the
WGS data [56, 57]. Also, mitochondrial specific variants
that are captured in the off-target regions are also mined
from our data (unpublished data). This provides valuable
information on the involvement of mitochondrial DNA in
disease pathology and/or could be used as a marker to
identify the individual affiliation with geography or eth-
nic group based on predicted mitochondrial haplogroup.
In addition to looking at any specific subset of genes
that might play a role in a particular organ or cell type,
one can also examine the status of imprinted genes and
identify unique allelic markers for the maternal and
Table 9 Cross-validation of the
structural variants identified
across various platforms: WGS,








LiPSC-ER2.2 IRF4 DEL no yes 0.27 0
DUSP22 DEL no yes 0.64 0
LOC283914 AMP no yes - −1
LOC146481 AMP no yes −4 0
LOC10013070 AMP no yes 2.85 -
PPP2R3B AMP no yes 1.3 0
LiPSC-GR1.1 SIX3 GAIN yes 1 4
SCN2A GAIN yes 2 -
GALNT3 GAIN yes 0 3
TTC21B GAIN yes −13 1
CSRNP3 GAIN yes (but as del) yes 0 3
TDGF1 GAIN yes 0 −1
NAV2 GAIN yes 0 1
HTATIP2 GAIN yes 0 0
SLC6A5 GAIN yes - -
NELL1 GAIN yes 1 0
LOC100126784 GAIN yes 1 0
DBX1 GAIN yes −1 -
PRMT3 GAIN yes 0 0
PLEKHA5 GAIN yes 0 0
AEB2 GAIN
GOLGA8B LOSS yes −2 0
GOLGA8A LOSS yes - -
MIR1233-1 LOSS
MIR1233-2 LOSS
HERC2P4 LOSS yes 1 2
LOC390705 LOSS yes 0 1
TP53TG3 LOSS yes 0 2
TP53TG3B LOSS
LOC653550 LOSS yes - −1
SLC6A10P LOSS yes −1 −1
GNAS GAIN yes 0 0
PPP2R3B GAIN yes yes 0 1
LOC286767 GAIN
MST4 GAIN yes −1 0
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paternal allele, allowing one to test expression of the ap-
propriate allele in an individual. Imprinted genes are
known to be important and expression from the paternal
or maternal allele can have important implications. Some
imprinted genes are altered during the reprogramming
process, and the H/igf axis is thought to be particularly
important in early development. Changes in expression
can underlie a variety of developmental abnormalities
and can alter the fate or quality of the differentiated cells
that are obtained. Other imprinted genes are thought to be
important in specific lineages. It is generally difficult to
test everything in every line but by having the WGS of
the line in a database, one can imagine inferring the phe-
notype when required by comparing the genomic se-
quence with RNA Seq performed at an appropriate time.
In particular, one may be able to determine if the X chro-
mosome is randomly inactivated or not as a complement
to the transcriptome analysis.
The WGS data can also be queried to cross examine the
SNP’s present or absent in the actual sample to provide better
clarity on the changes seen in CGH/SNP chip analysis, as lack
of hybridization could be due to absence of the SNP or allelic
variability. We have shown (unpublished data) that a virtual
SNP-CHIP result can be generated from WGS and a subset
from exome sequencing SNP’s. This may bemore relevant for
ethnic subgroups and can be used as an independent verifica-
tion of the SNP-CHIP result. The importance of such an anal-
ysis is highlighted by the lack of overlap seen between the
WGS and SNP/CHIP hybridization results (see results).
Others have made similar observations. Rogers and col-
leagues [58] have evaluated on the levels of discordance
across sequencing, imputation and microarray platforms and
reported that the most common type of discordance comes
from missing genotypes on the sequence technology, which
occurred most frequently when the microarray technology
identified at least 1 reference allele at the variant site.
We show that array-based transcritpome analysis can be
used to assess overall interchangeability of the starting popu-
lation using a R2 correlation co-efficient or comparing the
profile with currently available databases such as Pluritest
[59, 60]. The RNA seq data, in addition, provides a comple-
ment to the more specific tests that are performed as standard
quality control and also allows us to go back and ask addition-
al questions as to the quality of the cells that one may not ask
routinely. For example, while we examine pluripotency using
a couple of markers we could easily use the array-based results
to identify another 150 potential pluripotency markers, or re-
examine if trophectoderm is a contaminant, or some cells have
already acquired a epiblast fate, or for distinguishing between
naïve and primed states. Having the transcriptome analysis in
a database may also allow one to assess batch-to-batch vari-
ability and define specs for any release criteria one may
establish.
We chose to use transcriptome analysis, SNP-CHIP
and exome sequencing rather than alternatives, because
we felt that these tests provide sufficient information and
represent the best cost-benefit compromise. These tests
are widely available, can be done worldwide and the
analysis pipeline is relatively standard. The tests provide
several internal controls and the data can be readily
cross-correlated. Furthermore, database repositories that
are geared to receiving such data-sets have been
established in multiple countries. We have also suggested
that while the tests themselves are of utility as internal
controls for any organization, we feel the tests could be
more widely applicable for comparisons across sites and
groups, provided uniformity in data collection and stor-
age was in place and comparators or calibration material
Table 10 Structural variants identified by WGS and its enrichment in any disease related pathways (if any)
Event No. after
filter














LiPSC-ER2.2 DEL 653 16797153 89 11 18 no no no















DUP 58 17376 462 0 0 no NA NA
Stem Cell Rev and Rep (2016) 12:394–420 415






















ABCC9 Predicted Maternal 27.4 50 2 3 26.0 54 5 5
ABCG8 Predicted Maternal 27.0 73 4 5 25.8 65 3 3
ACD Predicted Maternal 26.5 2 23.0 1
ADAMTS16 Predicted Maternal 28.0 254 20 23 26.0 319 20 24
AIM1 Imprinted Paternal 29.3 82 4 10 23.4 54 4
ALDH1L1 Predicted Maternal 25.5 148 3 9 25.9 47 6 6
ANO1 Imprinted Maternal 22.8 42 1 2 26.0 1
APBA1 Predicted Paternal 29.0 118 8 11 27.5 8 4
ATP10A Imprinted Maternal 25.3 256 12 18 24.0 203 10 20
B4GALNT4 Predicted Maternal 24.3 17 2 1 23.4 21 3 1
BLCAP Imprinted Isoform
Dependent
23.8 12 5 26.5 4 3 1
BMP8B Predicted Paternal 23.4 3 22.4 10 2
BTNL2 Predicted Maternal 27.8 34 2 3 25.5 80 4 6
C10orf91 Predicted Maternal 25.5 1 35.0
C20orf20 Predicted Maternal 25.4 14 1 2 27.8 14 1 2
C9orf116 Predicted Paternal 18.9
C9orf85 Predicted Paternal 27.9 3 26.8
CCDC85A Predicted Paternal 27.1 245 19 14
CDH18 Predicted Paternal 28.3 893 83 94 25.6 244 28 29
CDK4 Predicted Maternal 24.3 1 2 21.8 3 1
CDKN1C Imprinted Maternal 27.0 1 15.0
CHMP2A Predicted Maternal 31.0 1 23.5 4
CHST8 Predicted Maternal 24.3 96 4 6 25.1 121 8 8
COL9A3 Predicted Maternal 23.1 50 2 2 21.9 34 6
CPA4 Imprinted Maternal 25.9 2 22.5 8 1 1
CSF2 Predicted Maternal 19.0 1 27.0
CYP1B1 Predicted Paternal 26.1 1 28.4 9 2
DDC Imprinted Isoform
Dependent
26.3 190 11 9 25.6 138 5 8
DGCR6 Imprinted Random 23.2 2 24.1 8 1
DGCR6L Imprinted Random 22.6 22.1 6 1
DIRAS3 Imprinted Paternal 15.0 1
DLGAP2 Imprinted Paternal 25.7 4 2 24.8 21 2 1
DLK1 Imprinted Paternal 20.4 9 1 21.7
DLX5 Imprinted Maternal 25.3 1 1 1 23.7 1 1
DNMT1 Imprinted Paternal 23.2 36 1 9 23.0 50 3 5
DVL1 Predicted Maternal 26.3 1 1 23.6 3 1
E2F7 Predicted Maternal 30.2 28 29.6 23 1
EGFL7 Predicted Paternal 21.2 1 22.1 23
EVX1 Predicted Paternal 24.0
FAM50B Imprinted Paternal 31.0 1 25.0 1
FBRSL1 Predicted Maternal 23.7 128 7 8 20.5 10 3
FERMT2 Predicted Paternal 29.0 6 28.2 86 11 3
FGFRL1 Predicted Maternal 21.6 19 1 2 22.9 17 4 2
FOXF1 Predicted Maternal 18.6 2 1 1 22.5 1
FOXG1 Predicted Paternal 27.8 54 4 25.0
FUCA1 Predicted Paternal 27.7 1
GAREM Predicted Paternal 27.9 36 4 3
GATA3 Predicted Paternal 24.3 28 4 1 21.0 9 1
GDAP1L1 Imprinted Paternal 27.0 3 1 24.3 2 1
GFI1 Predicted Paternal 26.0 9 2 23.4 10 3
GLI3 Predicted Maternal 27.8 234 19 16 25.5 299 21 18
GLIS3 Imprinted Paternal 26.3 517 22 36 25.5 611 25 37
GNAS Imprinted Isoform
Dependent
28.0 68 8 4 26.8 32 2 4
GPT Predicted Maternal 15.0 1 20.5
GRB10 Imprinted Isoform
Dependent
27.1 246 13 20 24.9 180 10 9
H19 Imprinted Maternal 21.5 6 22.2 6
HOXA11 Predicted Maternal 23.1 4 1 24.8 1
HOXA2 Predicted Maternal 31.0 19.5 1























HOXA3 Predicted Maternal 26.5 5 3 1 22.7 11 2 1
HOXA4 Predicted Maternal 21.0 25.0
HOXA5 Predicted Maternal 19.0 37.0 2
HOXB2 Predicted Maternal 25.2 3 1 1 27.5
HOXB3 Predicted Maternal 25.2 15 1 2 22.9 7
HOXC4 Predicted Maternal 26.3 13 6 5 24.1 24 1 8
HOXC9 Predicted Maternal 23.3 4 21.0 1
HSPA6 Predicted Maternal 23.5 1 23.8 4
HYMAI Imprinted Paternal 27.0 21.5 2 1
IFITM1 Predicted Maternal 24.5 1 13.0
IGF2 Imprinted Paternal 21.8 1 2 22.1 20 4
ISM1 Predicted Paternal 26.8 121 5 13 25.5 48 4 5
KBTBD3 Predicted Paternal 31.8 5 1 29.5 2 1
KCNK9 Imprinted Maternal 24.1 135 5 4 23.0 38 1 3
KCNQ1 Imprinted Maternal 25.7 343 13 25 23.6 212 11 11
KCNQ1DN Imprinted Maternal 14.0 1 21.0
KLF14 Imprinted Maternal 21.7 2 18.4 3
L3MBTL Imprinted Paternal 25.2 2 21.5 14
LDB1 Predicted Maternal 22.0 4 21.8 1 1
LILRB4 Predicted Maternal 21.4 7 21.4 7 1
LIN28B Imprinted Paternal 26.9 17 1 5 27.6 48 3 4
LMX1B Predicted Maternal 24.0 68 8 5 24.1 53 1 3
LRRTM1 Imprinted Paternal 15.5 1
LY6D Predicted Paternal 27.3 3 1 25.0
MAGEL2 Imprinted Paternal 33.5 2
MAGI2 Imprinted Maternal 29.4 1035 78 79 27.4 1485 120 112
MEG3 Imprinted Maternal 22.1 21 2 3 21.7 24 1
MEG8 Imprinted Maternal 21.1 2 19.7 6
MEST Imprinted Paternal 26.3 9 26.4 16 1
MESTIT1 Imprinted Paternal 29.5 2 23.0 1
MIMT1 Imprinted Paternal 27.0 28.2
MYEOV2 Predicted Paternal 23.7 16 1 21.5
MZF1 Predicted Maternal 23.8 4 24.7 12 1
NAA60 Imprinted Maternal 24.0 10 1 23.5
NAP1L5 Imprinted Paternal 25.5 1 1
NDN Imprinted Paternal 26.0 1 22.0 1
NKAIN3 Predicted Paternal 27.2 539 28 35 25.9 924 69 53
NKX6-2 Predicted Maternal 19.0
NLRP2 Imprinted Maternal 22.5 62 5 4 20.5 39 5
NPAP1 Imprinted Unknown 25.0 1 1 24.0
NTM Imprinted Maternal 28.2 793 53 68 25.9 585 49 49
OBSCN Predicted Paternal 25.2 160 7 7 23.7 169 10 6
OR11L1 Predicted Paternal 24.7 23.4
OSBPL5 Imprinted Maternal 23.8 115 9 9 22.4 89 4 4
OTX1 Predicted Maternal 21.8 4 20.7 3
PAOX Predicted Maternal 25.8 6 1 21.2 2 1
PEG10 Imprinted Paternal 34.6 2 1 27.0 4
PEG3 Imprinted Paternal 25.4 1 23.7 2
PEX10 Predicted Maternal 19.8 8 1 19.5 12
PHLDA2 Imprinted Maternal 16.0 1
PHPT1 Predicted Maternal 21.5
PLAGL1 Imprinted Paternal 28.2 29 3 4 26.6 13 2 1
PPAP2C Predicted Maternal 18.3 16 1 26.3 276 16 26
PPP1R9A Imprinted Maternal 26.5 71 4 9 22.1 12 2
PRDM16 Predicted Paternal 21.8 231 10 17 21.7 382 10 19
PTPN14 Predicted Maternal 27.0 10 2 3 27.3 55 4 6
PURG Predicted Paternal 28.2 26.8 20 3 2
PYY2 Predicted Paternal 31.0 1
RAB1B Predicted Maternal 25.1 7 2 2 23.7 3 1
RB1 Imprinted Maternal 26.9 52 7 9 26.2 11 1 1
RBP5 Imprinted Maternal 32.0 1 1 18.8 1 1
RPL22 Predicted Paternal 31.9 7 26.0 1
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was available. In principle, any line can be used as long
as it is widely available, stable and well characterized.
We have proposed that a set of ten lines that we gener-
ated at the NIH, which are widely disseminated and are
well characterized and have been grown in different cul-
ture conditions and have been shown to differentiate into
the major phenotypes of interest, could serve as such
calibration material. The NIH has generated whole ge-
nome sequencing data and in association with RUDCR
(Rutgers) SNP-CHP/CGH and RNA-SEQ data, and as
such, these lines could serve such a purpose.
It is important to emphasize that these tests are by no
means an absolute standard, and certainly do not enable
complete characterization of lines. For example, one can
miss many epigenetic changes that may be important, or
one may miss point mutations or inversions given the
depth and resolution of the analysis we have chosen.
We feel, however, these tests are a critical first step in
developing a database of information that can offer a
path to developing cheaper, more focused tests, as infor-
mation on the lines evolves and provides a path to more
rigorous testing, at a time when costs for more detailed
testing decrease.
In summary, we have shown that for a relatively modest
investment useful additional information can be obtained, and
this information if shared widely and accumulated in a data-
base along with data from calibration material will allow us to























RTL1 Imprinted Paternal 20.3 3 22.0 1
SALL1 Predicted Maternal 26.9 2 2 23.3 5 3 1
SGCE Imprinted Paternal 30.3 18 3 2 28.8 17 3 1
SGK2 Imprinted Paternal 23.3 6 1 1 25.1 18 2 1
SIM2 Predicted Paternal 26.9 28 3 2 24.2 16 1
SLC22A18 Imprinted Maternal 22.8 29 3
SLC22A18AS Provisional
Data
Maternal 22.3 56 4 1
SLC22A2 Imprinted Maternal 28.9 5 1 25.8 4
SLC22A3 Imprinted Maternal 27.0 82 2 8 26.8 119 2 7
SLC26A10 Predicted Maternal 27.0 1 25.7 2
SLC4A2 Predicted Maternal 21.6 1 23.2 9
SNRPN Imprinted Paternal 24.9 117 15 13 24.3 156 9 18
SNURF Imprinted Paternal 25.7 13 2 2
SOX8 Predicted Paternal 19.1 10 20.9 1
SPON2 Predicted Paternal 21.7 30 2 22.3 1 1
TCEB3C Imprinted Maternal 73.0 1
TFPI2 Imprinted Maternal 24.0
TIGD1 Predicted Paternal 28.4 7 25.6 7
TMEM52 Predicted Paternal 24.7 2 1 16.0
TMEM60 Predicted Paternal 29.0 3 28.3 1
TP73 Imprinted Maternal 23.6 73 4 5 23.0 93 3 7
TSHZ3 Predicted Paternal 26.6 34 4 8 24.7 77 7 10
UBE3A Imprinted Maternal 28.3 11 1 2 26.6 105 7 10
VAX2 Predicted Maternal 28.0 27 2 4 24.7 14 3 2
VENTX Predicted Maternal 25.0 1 24.0 12
WT1 Imprinted Paternal 28.3 53 4 2 24.9 9 1 3
ZC3H12C Imprinted Paternal 28.0 106 7 11 26.9 102 9 18
ZDBF2 Imprinted Paternal 28.4 10 2 29.8 7
ZFAT Imprinted Paternal 24.1 2 1 23.1 268 9 16
ZFAT-AS1 Imprinted Paternal 28.6 7
ZFP36L2 Predicted Maternal 21.0 1 1 15.0 1
ZIC1 Predicted Maternal 37.7 2 1 30.7 2 1
ZIM2 Imprinted Paternal 26.0 1 23.8 14
ZNF225 Predicted Paternal 22.1 25.4 1
ZNF229 Predicted Maternal 27.5 4 2 25.8 22 5
ZNF264 Unknown Unknown 27.1 34 5 2 25.2 30 1 4
ZNF597 Imprinted Maternal 33.0 1 1 24.8 1
For each cell line the mean depth of the alternate allele, the number of heterozygous and homozygous variants identified from WGS is provided
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strategy to assess Haplobanks and other models for delivering
cell-based therapy.
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